Invesco
SION

Invesco’s Sionna Therapeutics SION Stock Holding History

Invesco’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$432K Sell
10,787
-100,375
-90% -$3.83M ﹤0.01% 3216
2025
Q4 		$4.57M Buy
+111,162
New +$4.22M ﹤0.01% 2276

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Invesco's SION Position: Q1 2026 in Review

Invesco reduced its Sionna Therapeutics (SION) stake by 90% in Q1 2026, selling an estimated $3.83M and leaving 10,787 shares worth $432K. The position accounts for ﹤0.01% of the portfolio, ranked #3216.

Invesco first reported a position in SION in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.57M in Q4 2025. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Invesco held 10,787 shares of Sionna Therapeutics worth $432K as of Q1 2026.
  • Invesco sold 100,375 Sionna Therapeutics shares in Q1 2026, an estimated $3.83M.
  • Sionna Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3216 holding.
  • Invesco first reported a position in Sionna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Invesco's Sionna Therapeutics position peaked at $4.57M in Q4 2025.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.